Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical trial. Eficacia de la combinación de simvastatina y rifaximina en pacientes con cirrosis descompensada para prevenir el desarrollo de ACLF: ensayo clínico multicéntrico aleatorizado, doble-ciego, controlado con placebo.

Trial Profile

Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical trial. Eficacia de la combinación de simvastatina y rifaximina en pacientes con cirrosis descompensada para prevenir el desarrollo de ACLF: ensayo clínico multicéntrico aleatorizado, doble-ciego, controlado con placebo.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Rifaximin (Primary) ; Simvastatin (Primary)
  • Indications Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top